Search results
Results from the WOW.Com Content Network
As of 2016, the EMA was roughly parallel to the drug part of the U.S. Food and Drug Administration (FDA), [53] but without centralisation. [54] The timetable for product approval via the EMA's centralised procedure of 210 days compares well with the average of 500 days taken by the FDA in 2008 to evaluate a product. [55]
The Heads of Medicines Agencies (HMA) is a network of both the human and veterinary medicines agencies of the European Economic Area. [1]The HMA co-operates with the European Medicines Agency and the European Commission (Directorate-General for Health and Food Safety) in the operation of the European medicines regulatory system.
State Agency of Medicines Zāļu valsts aģentūra (ZVA) 2004 Liechtenstein: Office of Healthcare Amt für Gesundheit (AG) 1995 Lithuania: State Medicines Control Agency (SMCA) 2009 Malaysia: National Pharmaceutical Regulatory Agency (NPRA) Bahagian Regulatori Farmasi Negara: 2002 Malta: Malta Medicines Authority (MMA) 2008 Mexico
The admission of a new state the Union is limited to liberal democracies and Freedom House ranks all EU states as being totally free electoral democracies. [54] All but 4 are ranked at the top 1.0 rating. [55] However, the exact political system of a state is not limited, with each state having its own system based on its historical evolution.
Amazon Cooperation Treaty Organization (ACTO): promotion of sustainable development of the Amazon Basin; AMEA: Asia, Middle East and Africa; America (AMER): Usage varies; it may refer to just the United States of America, or just North America, or all of North and South America combined, or some other combination.
This is a list of Portuguese administrative divisions by GDP and GDP per capita. ... Portugal average 1 Greater Lisbon: 84,263,000,000 31.5% 39,942 158.0% 2
A further advantage of the Certification procedure [17] is that it provides the Ph. Eur. Commission [14] with up-to-date information on the quality of substances on the European market, highlighting where Ph. Eur. texts and quality requirements might require revision and helping to ensure that the pharmacopoeia remains state-of-the-art.
The Innovative Medicines Initiative (IMI) is a public-private partnership designed by the European Commission and EFPIA. It is a pan-European collaboration that brings together large biopharmaceutical companies, small- and medium-sized enterprises (SMEs), patient organisations, academia, hospitals and public authorities.